Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 97

Similar articles for PubMed (Select 23732307)

1.

Laninamivir octanoate for post-exposure prophylaxis of influenza in household contacts: a randomized double blind placebo controlled trial.

Kashiwagi S, Watanabe A, Ikematsu H, Awamura S, Okamoto T, Uemori M, Ishida K.

J Infect Chemother. 2013 Aug;19(4):740-9. doi: 10.1007/s10156-013-0622-9. Epub 2013 Jun 4.

2.

Neuraminidase inhibitors for preventing and treating influenza in children (published trials only).

Wang K, Shun-Shin M, Gill P, Perera R, Harnden A.

Cochrane Database Syst Rev. 2012 Apr 18;4:CD002744. doi: 10.1002/14651858.CD002744.pub4. Review.

PMID:
22513907
3.

Neuraminidase inhibitors for preventing and treating influenza in children.

Wang K, Shun-Shin M, Gill P, Perera R, Harnden A.

Cochrane Database Syst Rev. 2012 Jan 18;1:CD002744. doi: 10.1002/14651858.CD002744.pub3. Review. Update in: Cochrane Database Syst Rev. 2012;4:CD002744.

PMID:
22258949
4.

Long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection.

Sugaya N, Ohashi Y.

Antimicrob Agents Chemother. 2010 Jun;54(6):2575-82. doi: 10.1128/AAC.01755-09. Epub 2010 Apr 5.

5.
6.

Inhaled zanamivir for the prevention of influenza in families. Zanamivir Family Study Group.

Hayden FG, Gubareva LV, Monto AS, Klein TC, Elliot MJ, Hammond JM, Sharp SJ, Ossi MJ; Zanamivir Family Study Group.

N Engl J Med. 2000 Nov 2;343(18):1282-9.

7.

Efficacy and safety of inhaled zanamivir in the prevention of influenza in community-dwelling, high-risk adult and adolescent subjects: a 28-day, multicenter, randomized, double-blind, placebo-controlled trial.

LaForce C, Man CY, Henderson FW, McElhaney JE, Hampel FC Jr, Bettis R, Kudule L, Harris J, Yates P, Tisdale M, Webster A.

Clin Ther. 2007 Aug;29(8):1579-90; discussion 1577-8.

PMID:
17919541
8.

Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza.

Ikematsu H, Kawai N.

Expert Rev Anti Infect Ther. 2011 Oct;9(10):851-7. doi: 10.1586/eri.11.112. Review.

PMID:
21973296
9.

The duration of fever and other symptoms after the initiation of laninamivir octanoate hydrate in the Japanese 2011-2012 influenza season.

Ikematsu H, Kawai N, Iwaki N, Kashiwagi S.

J Infect Chemother. 2014 Feb;20(2):81-5. doi: 10.1016/j.jiac.2013.07.013. Epub 2013 Dec 11.

PMID:
24486167
10.

Comparison of the clinical effectiveness of zanamivir and laninamivir octanoate for children with influenza A(H3N2) and B in the 2011-2012 season.

Koseki N, Kaiho M, Kikuta H, Oba K, Togashi T, Ariga T, Ishiguro N.

Influenza Other Respir Viruses. 2014 Mar;8(2):151-8. doi: 10.1111/irv.12147. Epub 2013 Aug 19.

11.

Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: A double-blind, randomized, noninferiority clinical trial.

Watanabe A, Chang SC, Kim MJ, Chu DW, Ohashi Y; MARVEL Study Group.

Clin Infect Dis. 2010 Nov 15;51(10):1167-75. doi: 10.1086/656802. Epub 2010 Oct 11.

12.
13.

Zanamivir prophylaxis: an effective strategy for the prevention of influenza types A and B within households.

Monto AS, Pichichero ME, Blanckenberg SJ, Ruuskanen O, Cooper C, Fleming DM, Kerr C.

J Infect Dis. 2002 Dec 1;186(11):1582-8. Epub 2002 Nov 6.

14.

Effect of a single inhalation of laninamivir octanoate in children with influenza.

Katsumi Y, Otabe O, Matsui F, Kidowaki S, Mibayashi A, Tsuma Y, Ito H.

Pediatrics. 2012 Jun;129(6):e1431-6. doi: 10.1542/peds.2011-2054. Epub 2012 May 21.

15.

Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial.

Welliver R, Monto AS, Carewicz O, Schatteman E, Hassman M, Hedrick J, Jackson HC, Huson L, Ward P, Oxford JS; Oseltamivir Post Exposure Prophylaxis Investigator Group.

JAMA. 2001 Feb 14;285(6):748-54.

PMID:
11176912
16.

Safety evaluation of laninamivir octanoate hydrate through analysis of adverse events reported during early post-marketing phase vigilance.

Nakano T, Okumura A, Tanabe T, Niwa S, Fukushima M, Yonemochi R, Eda H, Tsutsumi H.

Scand J Infect Dis. 2013 Jun;45(6):469-77. doi: 10.3109/00365548.2012.763104. Epub 2013 Feb 4.

PMID:
23373850
17.

Clinical efficacy of long-acting neuraminidase inhibitor laninamivir octanoate hydrate in postmarketing surveillance.

Kashiwagi S, Yoshida S, Yamaguchi H, Mitsui N, Tanigawa M, Shiosakai K, Yamanouchi N, Shiozawa T, Yamaguchi F.

J Infect Chemother. 2013 Apr;19(2):223-32. doi: 10.1007/s10156-012-0481-9. Epub 2012 Oct 20.

PMID:
23085742
18.

Inhaled zanamivir versus placebo for the prevention of influenza outbreaks in an unvaccinated long-term care population.

Ambrozaitis A, Gravenstein S, van Essen GA, Rubinstein E, Balciuniene L, Stikleryte A, Crawford C, Elliott M, Shult P.

J Am Med Dir Assoc. 2005 Nov-Dec;6(6):367-74.

PMID:
16286057
19.

Efficacy of a single intravenous administration of laninamivir (an active metabolite of laninamivir octanoate) in an influenza virus infection mouse model.

Kakuta M, Kubo S, Tanaka M, Tobiume S, Tomozawa T, Yamashita M.

Antiviral Res. 2013 Oct;100(1):190-5. doi: 10.1016/j.antiviral.2013.08.004. Epub 2013 Aug 15.

PMID:
23954190
20.

Oseltamivir and inhaled zanamivir as influenza prophylaxis in Thai health workers: a randomized, double-blind, placebo-controlled safety trial over 16 weeks.

Anekthananon T, Pukrittayakamee S, Ratanasuwan W, Jittamala P, Werarak P, Charunwatthana P, Suwanagool S, Lawpoolsri S, Stepniewska K, Sapchookul P, Puthavathana P, Fukuda C, Lindegardh N, Tarning J, White NJ, Day N, Taylor WR.

J Antimicrob Chemother. 2013 Mar;68(3):697-707. doi: 10.1093/jac/dks418. Epub 2012 Nov 9. Erratum in: J Antimicrob Chemother. 2013 Jul;68(7):1695. Pukritayakamee, S [corrected to Pukrittayakamee, S].

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk